Alterations in Oral Microbiota of Differentiated Thyroid Carcinoma Patients With Xerostomia After Radioiodine Therapy

被引:8
|
作者
Lin, Baiqiang [3 ]
Zhao, Fuya [3 ,6 ]
Liu, Yang [1 ,2 ,3 ]
Sun, Jiayu [3 ,7 ]
Feng, Jing [3 ]
Zhao, Lei [3 ]
Wang, Haoran [3 ]
Chen, Hongye [3 ]
Yan, Wei [3 ]
Guo, Xiao [3 ]
Shi, Shang [3 ]
Li, Zhiyong [3 ]
Wang, Shuang [3 ]
Lu, Yu [3 ]
Zheng, Jianjun [4 ,5 ]
Wei, Yunwei [1 ,2 ,3 ]
机构
[1] Univ Chinese Acad Sci, HwaMei Hosp, Pancreat & Gastrointestinal Surg Div, Ningbo, Peoples R China
[2] Ningbo Clin Res Ctr Digest Syst Tumors, Ningbo, Peoples R China
[3] Harbin Med Univ, Affiliated Hosp 1, Oncol & Laparoscopy Surg, Harbin, Peoples R China
[4] Univ Chinese Acad Sci, HwaMei Hosp, Imaging Ctr, Ningbo, Peoples R China
[5] Ningbo Clin Med Res Ctr Imaging Med, Ningbo, Peoples R China
[6] Fujian Med Univ, Affiliated Hosp 1, Gastrointestinal Surg, Fuzhou, Peoples R China
[7] SouthernMed Univ, Zhujiang Hosp, Gen Surg, Guangzhou, Peoples R China
来源
基金
中国国家自然科学基金;
关键词
oral microbiota; xerostomia; differentiated thyroid carcinoma; radioiodine therapy; 16S rRNA; SALIVARY-GLAND FUNCTION; RADIOACTIVE IODINE; CANCER; INFLAMMATION; LIPOPOLYSACCHARIDE; RADIATION; CAVITY;
D O I
10.3389/fendo.2022.895970
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and AimsOral xerostomia remains one of the most common complications of differentiated thyroid carcinoma patients (DTC) after radioiodine therapy (RAI). Environmental factors in the etiology of xerostomia are largely unknown. We aimed to characterize the oral microbiota signatures and related biological functions associated with xerostomia and identify environmental factors affecting them. MethodsSaliva was collected from 30 DTC patients with xerostomia (XAs), 32 patients without xerostomia (indicated as non-XAs) following RAI after total thyroidectomy, and 40 healthy people (HCs) for 16S rRNA sequencing analysis. ResultsThe oral microbiota of XAs and non-XAs exhibited significant differences in alpha and beta diversities and bacterial taxa. The abundance of porphyromonas, fusobacterium, and treponema_2 were significantly higher in XAs, while the abundance of the streptococcus was lower in the microbiota of non-XAs. Fusobacterium, and porphyromonas were negatively correlated with unstimulated/stimulated whole salivary secretion (USW)/(SWS), while fusobacterium, porphyromonas, and treponema_2 genera levels were positively associated with cumulative radioiodine dose. PICRUSt2 and BugBase suggested a significant difference in the expression of potentially_pathogenic, anaerobic, gram_negative, the arachidonic acid metabolism, and lipopolysaccharide (LPS) biosynthesis between XAs and non-XAs, possibly interdependent on radioiodine-induced inflammation. NetShift analysis revealed that porphyromonas genus might play as a key driver during the process of xerostomia. Five genera effectively distinguished XAs from non-XAs (AUC = 0.87). ConclusionOur study suggests for the first time that DTC patients with xerostomia after RAI display microbiota profiles and associated functional changes that may promote a pro-inflammatory environment. Dysbiosis of the oral microbiota may contribute to exacerbating the severity of xerostomia. Our results provide a research direction of the interaction mechanism between oral microbiota alteration and the progress of xerostomia.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Radioiodine Therapy Induced Cytotoxicity in Patients with Differentiated Thyroid Carcinoma
    Hooman, A.
    Mogharrabi, M.
    Solooki, M.
    Mosaffa, N.
    Tabeie, F.
    Shafiee, B.
    Asli, Neshandar, I
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2008, 6 (03) : 135 - 139
  • [2] Radioiodine uptake by thyroglossal duct remnant after radioiodine therapy for differentiated thyroid carcinoma
    Jinguji, M.
    Nakajo, M.
    Tani, A.
    Yoshiura, T.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S783 - S784
  • [3] RADIOIODINE THERAPY FOR DIFFERENTIATED THYROID-CARCINOMA
    CONNOR, CS
    THOMAS, JH
    ROBINSON, RG
    PRESTON, DF
    HERMRECK, AS
    AMERICAN JOURNAL OF SURGERY, 1988, 156 (06): : 519 - 521
  • [4] Differentiated thyroid carcinoma referred for radioiodine therapy
    Al-Balawi, IA
    Meir, HM
    Yousef, MK
    Nayel, HA
    Al-Mobarak, MF
    SAUDI MEDICAL JOURNAL, 2001, 22 (06) : 497 - 503
  • [5] RADIOIODINE THERAPY IN DIFFERENTIATED THYROID-CARCINOMA
    EILLES, C
    NUKLEARMEDIZINER, 1991, 14 (01): : 19 - 25
  • [6] The ablative radioiodine therapy of differentiated thyroid carcinoma
    Rottenburger, Christof
    Lutz, Thomas
    THERAPEUTISCHE UMSCHAU, 2020, 77 (09) : 427 - 431
  • [7] Second primary malignancies after radioiodine therapy for differentiated thyroid carcinoma
    Macedo, R.
    Costa, G.
    Albuquerque, A.
    Pedroso de Lima, J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 : S343 - S343
  • [8] Radioiodine therapy after pretreatment with bexarotene for metastases of differentiated thyroid carcinoma
    Liu, Ying Y.
    Stokkel, Marcel P.
    Morreau, Hans A.
    Pereira, Alberto M.
    Romijn, Johannes A.
    Smit, Johannes W. A.
    CLINICAL ENDOCRINOLOGY, 2008, 68 (04) : 605 - 609
  • [9] TESTICULAR FUNCTION AFTER RADIOIODINE THERAPY FOR DIFFERENTIATED THYROID-CARCINOMA
    PACINI, F
    ELISEI, R
    GASPERI, M
    MASINI, I
    CECCARELLI, C
    FUGAZZOLA, L
    ANNALES D ENDOCRINOLOGIE, 1988, 49 (03) : 197 - 197
  • [10] SOMATIC RISKS OF RADIOIODINE THERAPY IN PATIENTS WITH DIFFERENTIATED THYROID-CARCINOMA
    PUSKAS, C
    SCIUK, J
    SCHOBER, O
    NUKLEARMEDIZINER, 1990, 13 (05): : 295 - 304